Myeloid-derived suppressor-like cells – does their frequency change in patients with different stages of CRC?

Irina Brčerević; Radoje Doder; Nenad Perišić; Stanko Petrović; Danilo Vojvodić

doi:10.2298/VSP220130091B

Irina Brčerević Military Medical Academy, Clinic for Gastroenterology and Hepatology, Belgrade, Serbia
Radoje Doder Military Medical Academy, Clinic for Gastroenterology and Hepatology, Belgrade, Serbia
Nenad Perišić Military Medical Academy, Clinic for Gastroenterology and Hepatology, Belgrade, Serbia
Stanko Petrović Military Medical Academy, Clinic for Gastroenterology and Hepatology, Belgrade, Serbia
Danilo Vojvodić Military Medical Academy, Institute for Medical Research, Belgrade, Serbia

DOI: https://doi.org/10.2298/VSP220130091B

Keywords: colorectal neoplasms, myeloid-derived suppressor cells, neoplasm metastasis, neoplasm staging

Abstract

Background/Aim. Colorectal cancer (CRC) is one of the most common cancers in the population, often leading to lethal outcomes. Myeloid-derived suppressor cells (MDSCs) belong to a heterogeneous group of immature cells thought to have an immunosuppressive effect that may aid in tumor development and spreading. The aim of this study was to analyze the frequency and significance of MDSC-like cells at different stages in patients with CRC. Methods. Peripheral blood (PB) samples of 83 patients at different stages of the disease and 12 healthy subjects (control group) were analyzed. MDSC-like cells were identified and enumerated in the PB samples of the participants based on the immunophenotypic characteristics of the cells. Results. A statistically significant increase in the absolute and relative number of polymorphonuclear (PMN) MDSC (PMN-MDSC)-like cells was observed in the PB of all the patients with CRC, compared to the healthy control group (p < 0.0001). No significant increase was observed in monocytic MDSC (M-MDSC)-like cells when they were analyzed without CRC stage stratification (p > 0.05). When the relative and absolute numbers of PMN-MDSC-like cells were analyzed in relation to the stages of CRC disease (TNM classification), a statistically significant difference was observed between the control group and patients in stages III and IV of the disease (p = 0.0005 vs. p = 0.0003 and p < 0.0001 vs. p < 0.0001, respectively). There was, as well, a significant difference when the numbers of PMN-MDSC-like cells in patients in stages I and II were compared to numbers in patients in stage IV of the CRC (p = 0.0161 vs. p < 0.0001 and p = 0.0065 vs. p < 0.0001, respectively). A statistically significant difference in the relative and absolute number of M-MDSC-like cells was observed only between patients in stages II and IV of the disease (p = 0.0014 and p = 0.0002, respectively). The highest number of MDSC-like cells was observed in stage IV of the disease according to the TNM classification. A positive correlation between the presence of these cells and the number of organs affected by metastatic changes was observed (p < 0.0001 for the relative and absolute number of PMN-MDSC-like cells and p = 0.003 and p = 0.0004 for the relative and absolute number of M-MDSC-like cells). Conclusion. CRC patients had a statistically significant increase in PMN-MDSC-like cells compared to healthy controls. The increase in absolute and relative numbers of these cells mostly follows the growth and progression of CRC, while a statistically significant difference in the number of M-MDSC-like cells is observed only between stages II and IV of the disease. The absolute and relative numbers of both subtypes of MDSC-like cells significantly correlate with the number of organs affected by CRC metastases.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71(3): 209‒49.

2. Bronte V, Serafini P, Apolloni E, Zanovello P. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J Immunother 2001; 24(6): 431–46.

3. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004; 4(12): 941‒52.

4. Ostrand-Rosenberg S. Myeloid derived-suppressor cells: their role in cancer and obesity. Curr Opin Immunol 2018; 51: 68‒75.

5. Gabrilovich D. Myeloid Derived Suppressor Cells. Cancer Immunol Res 2017; 5(1): 3‒8.

6. Tcyganov E, Mastio J, ChenE, Gabrilovich DI. Plasticity of myeloid-derived suppressor cells in cancer. Curr Opin Immunol 2018; 51: 76‒82.

7. Lu LC, Chang CJ, Hsu CH. Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives. J Hepatocell Carcinoma 2019; 6: 71–84.

8. Condamine T, Dominguez GA, Youn JI, Kossenkov AV, Mony S, Alicea-Torres K, et al. Lectin-type oxidized LDL receptor 1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci Immunol 2016; 1(2): aaf8943.

9. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 2016; 7: 12150.

10. Ma P, Beatty PL, McKolanis J, Brand R, Schoen RE, Finn OJ. Circulating Myeloid Derived Suppressor Cells (MDSC) That Accumulate in Premalignancy Share Phenotypic and Functional Characteristics With MDSC in Cancer. Front Immunol 2019; 10: 1401.

11. Gabrilovich D, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9(3): 162‒74.

12. OuYang LY, Wu XJ, Ye SB, Zhang RX, Li ZL, Liao W, et al. Tumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer. J Transl Med 2015; 13: 47.

13. Stanojević I, Miller K, Kandolf-Sekulović L, Mijušković Z, Zolotarevski L, Jović M, et al. A subpopulation that may correspond to granulocytic myeloid-derived suppressor cells reflects the clinical stage and progression of cutaneous melanoma. Int Immunol 2016; 28(2): 87‒97.

14. Safarzadeh E, Hashemzadeh S, Duijf P, Mansoori B, Khaze V, Mohammadi A, et al. Circulating myeloid‐derived suppressor cells: An independent prognostic factor in patients with breast cancer. J Cell Physiol 2019; 234(4): 3515–25.

15. Khaled YS, Ammori BJ, Elkord E. Increased Levels of Granulocytic Myeloid-Derived Suppressor Cells in Peripheral Blood and Tumour Tissue of Pancreatic Cancer Patients. J Immunol Res 2014; 2014: 879897.

16. Yamauchi Y, Safi S, Blattner C, Rathinasamy A, Umansky L, Juenger L, et al. Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non–Small Cell Lung Cancer.American Journal of Respiratory and Critical Care Medicine 2018; 198(6): 777–87.

17. Cai W, Qin A, Guo P, Yan D, Hu F, Yang Q, Hu F, Yang Q, Xu M, et al. Clinical significance and functional studies of myeloid-derived suppressor cells in chronic hepatitis C patients. J Clin Immunol 2013; 33(4): 798–808.

18. XiQ, Li Y, Juan Dai, Chen W. High frequency of mononuclear myeloid-derived suppressor cells is associated with exacerbation of inflammatory bowel disease. Immunol Invest 2015; 44(3): 279–87.

19. Schrijver IT, Théroude C, Roger T. Myeloid-Derived Suppressor Cells in Sepsis. Front Immunol 2019; 10: 327.

20. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-Fluorouracil selectively kills Tumor-Associated Myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010; 70(8): 3052‒61.

21. De Cicco P, Ercolano G, Ianaro A. The new era of cancer immunotherapy: Targeting Myeloid-derived suppressor cells to overcome immune evasion. Front Imunol 2020; 11: 1680.

22. Yuan L, Xu B, Fan H, Yuan P, Zhao P, Suo Z, et al. Pre- and post-operative evaluation: percentages of circulating myeloid-derived suppressor cells in rectal cancer patients. Neoplasma 2015; 62(2): 239‒49.

23. Lee WC, Wang YC, Cheng CH, Wu TH, Lee CF, Wu TJ, et al. Myeloid-derived suppressor cells in the patients with liver resection for hepatitis B virus-related hepatocellular carcinoma. Sci Rep 2019; 9(1): 2269.

24. Zhang B, Wang Z, Wu L, Zhang M, Li W, Ding J, et al. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS One 2013; 8(2): e57114.

25. Toor SM, Khalaf S, Murshed K, Abu Nada M, Elkord E. Myeloid cells in circulation and tumor microenvironment of Colorectal cancer patients with early and advanced disease stages. J Immunol Res 2020; 2020: 9678168.

26. Hossaini F, Al-Khami AA, Wyczechowska D, Hernandez C, Zheng L, Reisset K, et al. Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies. Cancer Immunol Res 2015; 3(11): 1236–47.

27. Karakasheva TA, Dominguez GA, Hashimoto A, Lin EW, Chiu C, Sasseret K, et al. CD38+ M-MDSC expansion characterizes a subset of advanced colorectal cancer patients. JCI Insight 2018; 3(6): e97022.

28. Chouaib S, Umansky V, Kieda C. The role of hypoxia in shaping the recruitment of proangiogenic and immunosuppressive cells in the tumor microenvironment. Contemp Oncol (Pozn) 2018; 22(1A): 7–13.

29. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumors. Nat Rev Immunol 2012; 12(4): 253‒68.

30. Condamine T, Mastio J, Gabrilovich DI. Transcriptional regulation of myeloid-derived suppressor cells. J Leukoc Biol 2015; 98(6): 913‒22.

31. Milrud CR, Bergenfelz C, Leandersson K. On the origin of myeloid-derived suppressor cell. Oncotarget 2017; 8(2): 3649‒65.

32. Shi H, Zhang J, Han X, Li H, Xie M, Sun Y, et al. Recruited monocytic myeloid-derived suppressor cells promote the arrest of tumor cells in the premetastatic niche through an IL-1beta-mediated increase in E-selectin expression. Int J Cancer 2017; 140(6): 1370–83.

33. Limagne E, Euvrard R, Thibaudin M, Rébé C, Derangère V, Chevriaux A, et al. Accumulation of MDSC and Th17 cells in patient with metastatic colorectal cancer predicts the efficacy of a FOLFOX-bevacizumab drug treatment regimen. Cancer Res 2016; 76(18): 5241‒52.

34. Fujita M, Kohanbash G, Fellows-Mayle W, Hamilton RL, Komohara Y, Decker SA, et al. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res 2011; 71(7): 2664‒74.

35. Bauer R, Udonta F, Wroblewski M, Ben-Batalla I, Santos IM, Taverna F, et al. Blockade of myeloid-derived suppressor cells expansion with all trans retinoic acid increases the efficacy of antiangiogenic therapy. Cancer Res 2018; 78(12): 3220‒32.

36. Walsh JE, Clark AM, Day TA, Gillespie MB, Young MR. Use of alpha 25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma. Hum Immunol 2010; 71(7): 659‒65.

37. Lin S, Wang J, Wang L, Wen J, Guo Y, Qiaoet W, et al. Phosphodiesterase-5 inhibition suppresses colonic inflammation-induced tumorigenesis via blocking the recruitment of MDSC. Am J Cancer Res 2017; 7(1): 41‒52.

38. Tavazioie MF, Pollack I, Tanqueco R, Ostendorf BN, Reis BS, Gonsalves FC, et al. LXR/ApoE activation restricts innate immune suppression in cancer. Cell 2018; 172(4): 825‒40.